For quality mesothelioma or lung cancer care in St. Louis, Missouri, there’s no better destination than the city’s world-famous Alvin J. Siteman Cancer Center. Siteman is the only Comprehensive Cancer Center in all of Missouri, meaning the National Cancer Institute (NCI) has designated it as maintaining the highest standards of excellence in patient care, clinical research, cancer prevention, education and basic science.
Not only is Siteman consistently ranked by U.S. News & World Report as one of the nation’s best cancer treatment centers, its parent institutions, Barnes-Jewish Hospital and Washington University School of Medicine, both rank highly as well. The staff of Siteman and its affiliated locations includes more than 350 research scientists and physicians from these institutions. Every year, the hospital treats about 8,000 newly diagnosed cancer patients, receiving more than $165 million in cancer research and related training grants in the process.
This dedicated community of specialists, including doctors and surgeons, nurses and researchers, utilizes a multidisciplinary approach to patient care. This is certainly beneficial for diagnosing and treating mesothelioma and lung cancer patients. Siteman has a malignant mesothelioma treatment team and is one of very few facilities to have its own dedicated chest surgery unit.
The hospital’s 22 lung cancer specialists are able to tackle the most difficult cases, including about 400 lung removals each year, in addition to about 570 new lung cancer cases each year. Among the centers specialists who treat mesothelioma and lung cancer are Douglas Adkins, M.D., a medical oncologist; Traves Crabtree, M.D., a thoracic surgeon specializing in minimally invasive procedures for lung and esophageal cancers and mediastinal and pleural diseases.
When treating mesothelioma, Siteman’s physicians typically rely on surgery and radiation to treat local tumors. Meanwhile, chemotherapy is used for the whole body, as it can be directed toward cancerous cells that may break away from the source.
Mesothelioma treatments may also depend on the disease’s stage. For instance, Stage I (the less advanced type) patients may undergo surgery to remove affected chest lining and tissues, followed by radiation therapy. However, patients with more advanced stages may undergo surgery to drain fluid in the chest, followed by radiation, chemotherapy or even combinations of these treatments. Palliative treatments, which are designed to improve quality of life by relieving the pain associated with symptoms, are used in conjunction with other treatments throughout the process of managing the disease.
Siteman surgeons are also utilizing biologic therapy (“immunotherapy”), an experimental treatment in which certain substances are used to boost the patient’s own immune system to fight the cancer.
Siteman is considered a leader in research for all cancer subtypes. But research for lung cancer and related conditions is a particular strength, as the program is actually ranked among the nation’s best.
The close partnership between Siteman and the medical and academic communities ensures the latest in diagnostic tests and cutting-edge treatments. The lung cancer specialists regularly participate in clinical cancer trials, such as “Phase I/II, Open-Label, Randomized Study of the Safety, Efficacy and Pharmacokinetics of Erlotinib With or Without PF-02341066 in Patients with Advanced Non-Small Cell Adenocarcinoma of the Lung (A8081002).”
Patients are able to participate in more than 250 clinical studies involving such paths as nanotechnology, bioinformatics, chemoprevention, pharmacogenetics, gene therapy, proteomics, imaging, genomics and leukemia and lymphoma.
Disclaimer: Alvin J. Siteman Cancer Center has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers. Read More